A large, single-centre UK registry of drotrecogin alfa-activated use

Macchiavello, L; Ellis, Gemma; Bowden, Steve; Smithies, M

doi:10.1186/cc5218

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests that experience in implementing the protocol may contribute to the greater observed treatment effect at high-enrolling sites. A similar effect might occur in routine clinical practice when physicians become more familiar with the indications for and optimal timing of drug administration, which was confirmed by data from the Polish registry [ 22 ] and from a recent UK single-centre study [ 50 ]. For these reasons, the SSC guidelines strongly encourage the use of a standardized policy in the ICU for the administration of DrotAA [ 4 ].…”

Section: Managing the Infusionmentioning

confidence: 60%

Practical aspects of treatment with drotrecogin alfa (activated)

Camporota

Wyncoll

2007

Critical Care

View full text Add to dashboard Cite

In November 2001, drotrecogin alfa (activated) was approved by the US Food and Drug Administration; in August 2002 it was approved by the European Medicines Agency. Since the approval of drotrecogin alfa (activated), however, critical care physicians have been faced with several challenges, namely its costs, selection of patients who are more likely to benefit from it, and the decision regarding when to start drotrecogin alfa (activated) treatment. There are also operational issues such as how to manage the infusion to deliver an effective treatment while minimizing the risk for bleeding, particularly in patients with deranged clotting, at around the time of surgery or during renal replacement therapy. While addressing these issues, this review remains practical but evidence based as much as possible.

show abstract

Section: Managing the Infusionmentioning

confidence: 60%